Schedule

November 1-2, 2011
Masur Auditorium on the NIH Campus
Building 10, Clinical Center
Bethesda, MD

Program Schedule

To view slides from a presenter click the icon next to the presentation title.

Tuesday, November 1
Moderator: David Stroncek, MD and John O'Shea, MD
8:30 am - 8:35 am	Welcome and Introductions David Stroncek, MD: National Institutes of Health
8:35 am - 8:45 am	Opening Remarks Joe Palca, PhD: National Public Radio
8:45 am - 9:30 am	Keynote Address Mahendra Rao, MD, PhD: NIH Center for Regenerative Medicine
9:30 am - 10:15 am	Mechanisms of Cellular Reprogramming Gustavo Mostoslavsky, MD, PhD: Boston University School of Medicine
10:15 am - 10:45 am	Break
10:45 am - 11:30 am	Improving Adoptive Cell Transfer-based Immunotherapies in Mice and Men Nick P. Restifo, MD: National Cancer Institute
11:30 am - 12:15 pm	Translation of iPSC Technology: Industrial, Pharmaceutical and Clinical-Grade Cells Peter Flynn, PhD: Fate Therapeutics Inc.
12:15 pm - 1:15 pm	Lunch (On Own)
1:15 pm - 2:00 pm	Enhancing NK Cell Cytoxicity Against Tumors Richard Childs: National Heart, Lung, and Blood Institute, NIH
2:00 pm - 2:45 pm	Role of Dendritic Cells in Immunotherapy of Established (Pre-) Malignant Lesions Cornelis Melief, MD, PhD: Leiden University Medical Center
2:45 pm - 3:15 pm	Regulatory Considerations for Cell Therapies Keith Wonnacott, PhD: Food & Drug Administration
3:15 pm - 3:45 pm	Break
3:45 pm - 4:15 pm	New Methods of Expanding T Cells Mark E. Dudley, PhD: National Cancer Institute, NIH
4:15 pm - 5:00 pm	Evaluation of Biomarkers for T Cell Therapies as Related to Anti-CD19 CAR Therapy Michael Kalos, PhD: University of Pennsylvania
Wednesday, November 2
Moderator: Cornelis Melief, MD, PhD
8:20 am - 8:30 am	Opening Remarks John Gallin, MD: National Institutes of Health
8:30 am - 9:15 am	Keynote Address: Adoptive Cell Therapy for Metastatic Cancer Steven Rosenberg, MD, PhD: National Cancer Institute, NIH
9:15 am - 10:00 am	Engineered Immunity and Acquired Immunity within an Adoptive Cell Transfer Therapy of Genetically Engineered T Cells for Metastatic Melanoma James Heath, PhD: California Institute of Technology
10:00 am - 10:30 am	Break
10:30 am - 11:15 am	Cell Phenotype for Long Term Persistence after Adoptive Immune Therapy Carolina Berger: Fred Hutchinson Cancer Research Center
11:15 am - 12:00 pm	Identification of Self-renewing, Multipotent CD8+ Memory Stem Cells in Mice and Humans Luca Gattinoni, MD: National Cancer Institute
12:00 pm - 12:30 pm	Clinical Trials from the CITN Martin "Mac" Cheever, MD: Fred Hutchinson Cancer Center; Jeffrey Miller, MD: University of Minnesota; Daniel Powell, PhD: University of Pennsylvania
12:30 pm - 1:00 pm	Closing Question & Answer Discussion Moderator: Cornelis Melief, MD, PhD

All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.